Hirsch Bradford R, George Daniel J, Harrison Michael R
Duke University Medical Center, Durham, North Carolina.
Clin Adv Hematol Oncol. 2014 Mar;12(3):163-71.
Meaningful progress has been realized in the treatment of metastatic renal cell carcinoma with the recent approval of a number of new agents; more new agents are on the horizon. Despite the recent completion of many clinical trials that have changed or will change practice, many questions remain. In this manuscript, we highlight the most noteworthy developments in the first- and second-line treatment of metastatic renal cell carcinoma, as these are the areas of greatest change. We also emphasize ongoing trials and those areas that are most in need of study in order to move the field forward. Although more data are needed, exciting progress is being made.
随着近期多种新药物获批，转移性肾细胞癌的治疗取得了有意义的进展；更多新药物即将问世。尽管最近完成了许多已经改变或将会改变治疗实践的临床试验，但仍有许多问题存在。在本手稿中，我们重点介绍转移性肾细胞癌一线和二线治疗中最值得关注的进展，因为这些是变化最大的领域。我们还强调了正在进行的试验以及为推动该领域发展最需要研究的领域。虽然还需要更多数据，但正在取得令人兴奋的进展。
